Literature DB >> 19373262

Deep sclerectomy and trabeculectomy in uveitic glaucoma.

B Dupas1, C Fardeau, N Cassoux, B Bodaghi, P LeHoang.   

Abstract

PURPOSE: To compare the results of deep sclerectomy (DS) and trabeculectomy (TRAB) in the management of uveitic glaucoma.
METHODS: A retrospective chart review was carried out of 41 eyes (38 patients) operated on for uncontrolled uveitic glaucoma, 20 by DS with an implant and 21 by TRAB, with antiproliferative agents in both cases. Main outcome criteria were intraocular pressure (IOP), flare values, complications, and need for postoperative adjustments or re-operation.
RESULTS: Mean follow-up lasted 21.1+/-11.3 months in the TRAB group and 18.9+/-10.7 months in the DS group (P=0.184). Mean IOP did not differ significantly in the two groups on the day before surgery, at postoperative days 1 and 7, or at months 1, 6, and 12. At postoperative month 12, IOP values in the TRAB and DS groups were 12.4+/-4.3 and 11.7+/-3.3 mm Hg (P=0.688), respectively. The cumulative probability of success at 12 months was 89% for TRAB and 88% for DS (P=0.306). After DS, more postoperative adjustments were necessary to lower IOP than after TRAB (85 vs 9.5%, P<0.001), but 7 days after surgery, intraocular inflammation was higher after TRAB (245.8 vs 38.5 ph/ms, P<0.001).
CONCLUSIONS: DS and TRAB afforded equivalent IOP control in uveitic glaucoma. TRAB involved deeper invasion of the eye and resulted in more inflammation during the week after surgery, but successful DS required closer postoperative monitoring and more postoperative adjustments.

Entities:  

Mesh:

Year:  2009        PMID: 19373262     DOI: 10.1038/eye.2009.82

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  12 in total

1.  Long-term results of ab externo trabeculotomy for glaucoma secondary to chronic uveitis.

Authors:  Bogomil Voykov; Spyridon Dimopoulos; Martin Alexander Leitritz; Deshka Doycheva; Antony William
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-10-31       Impact factor: 3.117

2.  Long-term efficacy of deep sclerectomy in Posner-Schlossman syndrome.

Authors:  Fiamma Campana; Guido Caramello; Laura Dallorto; Teresa Rolle
Journal:  BMJ Case Rep       Date:  2015-01-23

3.  The influence of mitomycin C concentration on the outcome of trabeculectomy in uveitic glaucoma.

Authors:  Faisal A Almobarak; Ali H Alharbi; Jose Morales; Ibrahim Aljadaan
Journal:  Int Ophthalmol       Date:  2017-10-14       Impact factor: 2.031

4.  Deep sclerectomy for uveitic glaucoma: long-term outcomes.

Authors:  K Mercieca; L Steeples; N Anand
Journal:  Eye (Lond)       Date:  2017-06-23       Impact factor: 3.775

5.  [Non-penetrating glaucoma surgery].

Authors:  T Klink; J Matlach; F Grehn
Journal:  Ophthalmologe       Date:  2012-08       Impact factor: 1.059

6.  Surgical outcomes of uveitic glaucoma.

Authors:  Ester Carreño; Sonia Villarón; Alejandro Portero; José M Herreras; José A Maquet; Margarita Calonge
Journal:  J Ophthalmic Inflamm Infect       Date:  2010-11-18

7.  European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 2: Classification and terminologySupported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 2 Classification and Terminology.

Authors: 
Journal:  Br J Ophthalmol       Date:  2017-04-18       Impact factor: 4.638

8.  Primary glaucoma surgery in Fuchs' heterochromic uveitis: a comparison of trabeculectomy versus deep sclerectomy.

Authors:  Andrew Walkden; Karl Mercieca; Divya Perumal; Nitin Anand
Journal:  Ther Adv Ophthalmol       Date:  2019-08-19

9.  Comparison of anterior chamber flare among different glaucoma surgeries.

Authors:  Masaki Tanito; Kaoru Manabe; Mihoko Mochiji; Yasuyuki Takai; Yotaro Matsuoka
Journal:  Clin Ophthalmol       Date:  2019-08-22

Review 10.  Current Approach in the Diagnosis and Management of Uveitic Glaucoma.

Authors:  Francisco J Muñoz-Negrete; Javier Moreno-Montañés; Paula Hernández-Martínez; Gema Rebolleda
Journal:  Biomed Res Int       Date:  2015-10-19       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.